Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) shares gapped down before the market opened on Thursday. The stock had previously closed at $17.43, but opened at $16.70. Daiichi Sankyo shares last traded at $17.2450, with a volume of 13,443 shares traded.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the company. Zacks Research downgraded Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Daiichi Sankyo has a consensus rating of “Reduce”.
Read Our Latest Report on Daiichi Sankyo
Daiichi Sankyo Trading Down 1.0%
The company has a 50 day simple moving average of $17.76 and a 200 day simple moving average of $17.52. The company has a current ratio of 2.92, a quick ratio of 1.96 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $31.98 billion, a PE ratio of 17.52, a P/E/G ratio of 1.78 and a beta of -0.10.
Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last announced its earnings results on Friday, October 30th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.08. The company had revenue of $3.77 billion for the quarter, compared to the consensus estimate of $3.58 billion. Daiichi Sankyo had a return on equity of 16.31% and a net margin of 12.13%. Analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 earnings per share for the current fiscal year.
About Daiichi Sankyo
Daiichi Sankyo is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions. Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib).
Further Reading
- Five stocks we like better than Daiichi Sankyo
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
- 3 Niche ETFs Are Beating the S&P 500, and Their Strategies Are Anything but Typical
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
